Serum Metabolomics Reveals the Effectiveness of Human Placental Mesenchymal Stem Cell Therapy for Crohn's Disease

Xiao Wang,Dandan Shang,Junyao Chen,Sheng Cheng,Deying Chen,Zhehua Zhang,Chaoxu Liu,Jiong Yu,Hongcui Cao,Liang Li,Lanjuan Li
DOI: https://doi.org/10.1016/j.talanta.2024.126442
IF: 6.1
2024-01-01
Talanta
Abstract:Mesenchymal stem cell (MSC) therapy offers a promising cure for Crohn's disease (CD), however, its therapeutic effects vary significantly due to individual differences. Therefore, identifying easily detectable biomarkers is essential to assess the efficacy of MSC therapy. In this study, SAMP1/Yit mice were used as a model of CD, which develop spontaneous chronic ileitis, closely resembling the characteristics present in CD patients. Serum metabolic alterations during treatment were analyzed, through the application of differential 12C-/13C-dansylation labeling liquid chromatography-mass spectrometry. Based on the significant differences and time-varying trends of serum amine/phenol-containing metabolites abundance between the control group, the model group, and the treatment group, four serum biomarkers were ultimately screened for evaluating the efficacy of MSC treatment for CD, namely 4-hydroxyphenylpyruvate, 4-hydroxyphenylacetaldehyde, caffeate, and N-acetyltryptamine, whose abundances both increased in the serum of CD model mice and decreased after MSC treatment. These metabolic alterations were associated with tyrosine metabolism, which was validated by the dysregulation of related enzymes. The discovery of biomarkers may help to improve the targeting and effectiveness of treatment and provide innovative prospects for the clinical application of MSC for CD.
What problem does this paper attempt to address?